; (ii) the anticipated lifespan of covered biotechnology equipment or services already or expected to be procured; (iii) the estimated costs and timeline to replace covered biotechnology equipment or services already procured; and (B) the domestic and international market share; (2) assess risks to national security posed by the entities identified under subsections (f)(1) and (g), obtaining active and future Federal grants to or contracts with private companies, academic institutions, and public sector entities; (3) develop a strategy to— (A) mitigate the risks to national security identified in the assessment conducted under paragraph (2); and (B) support private companies, academic institutions, and public sector entities seeking to acquire covered biotechnology equipment or services from alternative entities